ArticleClinical and experimental medicine2025
METTL3 stabilizes DDX17 mRNA via IGF2BP2-mediated m6A modification to suppress endometrial cancer progression.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact ofInternational journal of medical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundEndometrial cancer (EC), a type of uterine cancer, is witnessing a global increase in incidence. Despite advancement in diagnosis and treatment, metastatic or recurrent EC often exhibits a poor prognosis, necessitating novel therapeutic strategies. DEAD-box helicase 17 (DDX17) is implicated in several cancers. Our study aimed to uncover the biological function and molecular mechanism of DDX17 in EC.
methodsEC and matched adjacent normal tissues from 80 patients were analyzed; DDX17 mRNA/protein expression was quantified via RT-qPCR and immunoblotting in clinical specimens and cell lines (HEC-1A, HEC-1B, Ishikawa), with functional assays (proliferation/migration/invasion) performed following DDX17 overexpression in vitro, while xenograft modeling in BALB/c nude mice enabled in vivo validation through immunofluorescence and immunohistochemical staining; mechanistic studies employed RNA immunoprecipitation (RIP-PCR), m6A-specific RNA immunoprecipitation (MeRIP-PCR), and protein interaction analyses.
resultsDDX17 was significantly downregulated in EC tissues/cells, correlating with poor prognosis in clinical cohorts. Overexpression of DDX17 suppressed tumorigenesis both in vitro and in vivo through PI3K/AKT pathway inactivation. METTL3-mediated m6A modification stabilized DDX17 mRNA, with IGF2BP2 specifically recognizing m6A-modified transcripts. Critically, METTL3 ablation reversed DDX17 stabilization and abolished its tumor-suppressive effects, while PI3K inhibition (LY294002) phenocopied METTL3 restoration in rescuing DDX17 deficiency-induced oncogenicity.
conclusionMETTL3-mediated m6A modification stabilizes DDX17 to suppress EC cell proliferation, migration, and invasion through an IGF2BP2-dependent mechanism by inactivating the PI3K/AKT pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.